Navigation Links
Catalent Signs Drug Development Agreement with Cybin Inc for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
Date:3/22/2021

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Cybin Inc (NEO:CYBN, OTCQB:CLXPF), a Canadian biotech company focused on progressing psychedelic therapeutics, to apply Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for the delivery of Cybin’s novel deuterated tryptamine (CYB003), a potential therapy for treatment-resistant psychiatric disorders.

Zydis technology creates a freeze-dried tablet that disperses almost instantly in the mouth without water and is recognized as one of the world’s best-performing ODTs. Delivering CYB003 in such a dose form could have significant benefits, as an ODT would allow pre-gastric delivery and prevent first pass metabolism, potentially improving the pharmacokinetic profile of the drug. The project is due to commence in April 2021 and will involve initial feasibility studies being conducted for the manufacturing and analytical testing of ODT doses containing varying quantities of CYB003, alongside different excipients.

Jonathan Arnold, President of Oral and Specialty Delivery at Catalent, commented, “We look forward to working with Cybin to potentially develop a novel and fast-acting therapy for treatment-resistant psychiatric disorders. The Zydis platform is an ideal technology to leverage for this type of drug formulation, as pre-gastric absorption is crucial for efficacy.”

Doug Drysdale, Cybin’s CEO, added, “We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of CYB003, recently acquired as part of our acquisition of Adelia Therapeutics. Our focus on reducing the need for health system resources, such as in-clinic therapist time, is an important part of our goal to create scalable, more accessible treatments for mental health disorders.”

Catalent’s 250,000 sq. ft. site in Swindon, U.K. houses the company’s Zydis development and manufacturing operation, which produces over one billion ODTs annually.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs around 15,000 people, including approximately 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

About Cybin Inc
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Visit http://www.cybin.com

Cybin Investor Contacts:

Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com

Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com

Cybin Media Contacts:

John Kanakis, Cybin Inc.
John@cybin.com

Annie Graf, KCSA Strategic Communications
agraf@kcsa.com

Faith Pomeroy-Ward, In-Site Communications, Inc.
Faith@insitecony.com

Read the full story at https://www.prweb.com/releases/catalent_signs_drug_development_agreement_with_cybin_inc_for_its_fast_dissolve_formulation_of_novel_deuterated_tryptamine_cyb003/prweb17810721.htm.


'/>"/>
Source: PRWeb
Copyright©2021 Vocus, Inc.
All rights reserved


Related biology news :

1. Technologies to Enhance Cell Line Productivity and Expand Antibody-Drug Conjugate Therapeutic Window to be Presented by Catalent Biologics at PEGS
2. Catalent Completes Purchase of Pharmaceutical Packaging Facility in Shiga, Japan
3. Catalent to Present Assessment Methods and Design Approaches for T-Cell Manufacturing Challenges at ISCT 2020 Virtual
4. Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity
5. Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
6. Catalent to Present Case Studies on Formulation Design for Early Phase Molecules and Discuss Benefits of Mass Spectrometry for HCP Analysis at AAPS PharmSci 360
7. Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
8. Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
9. Planning for Orphan Drug Supply to be Discussed by Catalent at World Orphan Drug Congress
10. Catalent Receives P&G External Business Partner of the Year Award
11. Acumed Signs Agreement with Vivorte to Distribute its Orthobiologics Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: